Subcutaneous Interferon- β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance
ConclusionSafety data from both clinical trial and post-marketing settings indicate that treatment with sc IFN- β1a does not increase stroke risk in patients with MS.FundingMerck KGaA, Darmstadt, Germany.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Germany Health | Merck | Multiple Sclerosis | Stroke | Study